Reuters logo
BRIEF-Mabvax Therapeutics signs research agreement with Memorial Sloan Kettering Cancer Center
2017年5月31日 / 上午11点18分 / 4 个月前

BRIEF-Mabvax Therapeutics signs research agreement with Memorial Sloan Kettering Cancer Center

May 31 (Reuters) - Mabvax Therapeutics Holdings Inc

* Mabvax Therapeutics signs research agreement with Memorial Sloan Kettering Cancer center to develop novel car t-cell based anti-cancer immunotherapies for treatment of pancreatic and small cell lung cancers

* Mabvax Therapeutics - co to provide funding to evaluate efficacy of multiple car t-cell products incorporating different antibody targeting sequences​

* Mabvax Therapeutics - has certain rights to new car t-cell inventions developed, including an exclusive time-limited option to license MSK’s rights in such inventions​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below